Moderna is dropping an IL-2 program in autoimmune disorders after AstraZeneca returned the rights, the mRNA leader announced Thursday in its third quarter filing.
GlaxoSmithKline scored a pivotal Priority Review from the FDA for its respiratory syncytial virus (RSV) vaccine candidate for older adults, which will expedite regulatory evaluation of its clinical data.
Indegene will leverage its healthcare domain expertise and experience in operating digital centers of excellence to help streamline AstraZeneca’s global content supply chain and orchestrate personalized customer journeys in an agile, global engagement model.
The company said its experimental drug capivasertib was able to help patients with an advanced form of breast cancer live longer, when combined with the drugmaker’s older cancer treatment Faslodex regardless of biomarker status.
Drugmaker AstraZeneca said on Tuesday that its asthma drug Fasenra failed to meet one of two main goals of a late-stage study assessing the treatment’s benefits in a chronic allergic condition that causes difficulty in swallowing.
The FDA greenlit AstraZeneca’s anti-CTLA-4 antibody tremelimumab in combination with its checkpoint inhibitor Imfinzi as a treatment for patients with unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer.
New Phase III data shows Novartis’ experimental iptacopan demonstrated superiority against AstraZeneca subsidiary Alexion’s Soliris and Ultomiris in paroxysmal nocturnal hemoglobinuria (PNH).
Attempts by Oxford University researchers and AstraZeneca Plc to create a nasal-spray version of their jointly developed COVID-19 shot suffered a setback on Tuesday as initial testing on humans did not yield the desired protection.
The top pharmaceutical companies and brands in this year’s Outcomes Creativity Index elevated their messaging by breaking down barriers, debunking myths and giving patients a stronger voice.
The top pharma companies in 2021 continued to be engaged in creating vaccines and therapeutics, and the investments in R&D led to greater revenue and earnings.